The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2021 | Sustained MRD negativity in multiple myeloma
Elena Zamagni
• 10 Sep 2021
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, talks on the benefits of measurable residual disease (MRD) for patients with multiple myeloma, describing how sustained MRD negativity can be used to provide patients with more information on their response to treatment. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
